The update on the rationale, use and selection of beta-blockers in heart failure.
OBJECTIVE
The purpose of this review was to describe important developments in the selection of beta-blockers in heart failure.


RESULTS
The superiority of carvedilol over metoprolol tartrate in one clinical trial is demonstrated, and multiple studies investigated the potential mechanisms of benefit. Current practice patterns still demonstrate the importance of understanding barriers to the effective use of beta-blocking agents.


CONCLUSIONS
There are continued refinements in the choice of beta-blockers in heart failure, but clearly an important remaining challenge is to modify health care delivery in an effort to maximize adherence to guidelines.
Giesler
Gregory
G
University of Texas-Houston and University of Texas-M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Lenihan
Daniel J
DJ
Durand
Jean-Bernard
JB
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D008790:Metoprolol